In a patient with mast cell activation syndrome (MCAS) after a retatrutide injection, what immediate evaluation and management steps should be taken?

Immediate Management of MCAS After Retatrutide Injection

If the patient is experiencing acute mast cell activation symptoms following retatrutide injection, immediately assess for anaphylaxis and administer epinephrine 0.3-0.5 mg IM if there is systemic involvement (hypotension, respiratory compromise, or multi-organ symptoms), then position the patient supine and initiate standard anaphylaxis protocols 1.

Immediate Assessment and Stabilization

Critical First Steps

• Check vital signs immediately: Look specifically for hypotension, tachycardia, respiratory distress, or oxygen desaturation
• Assess for anaphylaxis criteria: Involvement of skin/mucosa PLUS either respiratory compromise OR cardiovascular instability OR severe gastrointestinal symptoms
• Position patient supine if any hypotensive symptoms are present—this is critical as patients with recurrent hypotensive episodes should assume supine position immediately 1

Acute Interventions Based on Presentation

For systemic anaphylaxis or airway involvement:

• Epinephrine autoinjector (0.3-0.5 mg IM) should be administered without delay 1
• Repeat every 5-15 minutes as needed
• Establish IV access and prepare for fluid resuscitation

For bronchospasm:

• Administer albuterol via nebulizer or metered-dose inhaler 1
• Consider additional bronchodilators as needed

For severe refractory symptoms:

• Consider IV corticosteroids (methylprednisolone 125 mg or equivalent) for prolonged episodes 2
• H1 and H2 antihistamines IV (diphenhydramine 25-50 mg IV and ranitidine 50 mg IV or famotidine 20 mg IV)

Diagnostic Confirmation

Obtain Serum Tryptase Levels

Critical timing: Draw serum tryptase within 1-4 hours of symptom onset to document mast cell activation 3, 4

• MCAS diagnostic criterion: Tryptase must increase by 20% + 2 μg/L above the patient's baseline 3
• If baseline tryptase is unknown, an acute level >11.4 μg/L suggests activation, though this alone is insufficient for MCAS diagnosis
• Important caveat: A normal tryptase does NOT rule out MCAS, as not all mast cell activation events cause tryptase elevation 4

Document Clinical Manifestations

Record specific symptoms across organ systems:

• Cutaneous: Flushing, pruritus, urticaria, angioedema (though notably, many MCAS patients do NOT present with classic skin findings) 5
• Cardiovascular: Hypotension, tachycardia, syncope
• Respiratory: Bronchospasm, wheezing, throat tightness
• Gastrointestinal: Nausea, vomiting, diarrhea, abdominal cramping
• Neurologic: Brain fog, headache, dizziness

Ongoing Management

Pharmacologic Stabilization

First-line prophylactic therapy (should be initiated or optimized):

1. H1 antihistamines: Non-sedating agents like cetirizine or fexofenadine at 2-4 times FDA-approved doses 1

   • Example: Cetirizine 20-40 mg daily or fexofenadine 360-720 mg daily
   • These work prophylactically, NOT acutely once symptoms manifest

2. H2 antihistamines: Famotidine 20-40 mg twice daily 1

   • Particularly helpful for gastrointestinal symptoms

3. Mast cell stabilizers: Consider sodium cromolyn 200 mg four times daily 2

   • May take weeks to show benefit

For refractory symptoms:

• Steroid burst: Prednisone 0.5 mg/kg/day with slow taper over 1-3 months 1
• Leukotriene inhibitors: Montelukast 10 mg daily if bronchospasm or GI symptoms predominate 1

Critical Pitfalls to Avoid

1. Do NOT wait for skin manifestations: Up to 87% of suspected MCAS patients do NOT report classic allergic skin symptoms like wheals or flushing 5

2. Do NOT rely solely on tryptase: Many genuine mast cell activation events occur without tryptase elevation; clinical criteria and response to therapy are equally important 4

3. Avoid first-generation antihistamines long-term (diphenhydramine, hydroxyzine) in elderly patients due to cognitive decline risk and anticholinergic effects 1

4. Do NOT dismiss symptoms as psychiatric: Over one-third of MCAS patients have been misdiagnosed with somatization or primary psychiatric disorders before correct diagnosis 6

Retatrutide-Specific Considerations

Given that retatrutide is a novel GLP-1/GIP/glucagon receptor agonist 7, consider:

• Drug-induced mast cell activation: The injection itself (subcutaneous route, excipients, or the drug mechanism) may have triggered degranulation
• Contraindication assessment: Document this reaction thoroughly as retatrutide may need to be permanently discontinued in this patient
• Alternative triggers: Evaluate if the reaction was to the drug itself versus injection site trauma, excipients, or concurrent exposures

Disposition and Follow-up

Prescribe before discharge:

• Epinephrine autoinjector (2 devices) with clear instructions on use 1
• Written anaphylaxis action plan
• Medical alert identification

Arrange urgent follow-up with allergist/immunologist for:

• Comprehensive MCAS workup including baseline tryptase, urinary mediator levels (histamine metabolites, prostaglandin D2 metabolites, leukotriene E4) 4
• Evaluation for clonal mast cell disorders (KIT D816V mutation, bone marrow biopsy if indicated) 8
• Assessment for secondary causes (IgE-mediated allergies, hereditary alpha tryptasemia) 8

Document thoroughly: This reaction should be reported to FDA MedWatch as an adverse drug event given retatrutide's recent approval 7.